These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 30231330)

  • 1. Acute Myeloid Leukemia: The Good, the Bad, and the Ugly.
    Kuykendall A; Duployez N; Boissel N; Lancet JE; Welch JS
    Am Soc Clin Oncol Educ Book; 2018 May; 38():555-573. PubMed ID: 30231330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Myeloid Leukemia Diagnosed 5 Years after Adult T-Cell Leukemia/Lymphoma.
    Owatari S; Arai A; Tsuruta T; Haraguchi K; Otsuka M; Hanada S
    J Clin Exp Hematop; 2015; 55(1):29-31. PubMed ID: 26106004
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations and MDM2(SNP309) identify subgroups of AML patients with impaired outcome.
    Falk IJ; Willander K; Chaireti R; Lund J; Nahi H; Hermanson M; Gréen H; Lotfi K; Söderkvist P
    Eur J Haematol; 2015 Apr; 94(4):355-62. PubMed ID: 25156865
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Core binding factor acute myeloid leukaemia and c-KIT mutations.
    Riera L; Marmont F; Toppino D; Frairia C; Sismondi F; Audisio E; Di Bello C; D'Ardia S; Di Celle PF; Messa E; Inghirami G; Vitolo U; Pich A
    Oncol Rep; 2013 May; 29(5):1867-72. PubMed ID: 23467883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of acute myeloid leukemia in patients with untreated chronic lymphocytic leukemia.
    Ito S; Fujiwara SI; Mashima K; Umino K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Ann Hematol; 2017 May; 96(5):719-724. PubMed ID: 28144729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in the diagnosis and treatment of secondary acute myeloid leukemia.
    Ossenkoppele G; Montesinos P
    Crit Rev Oncol Hematol; 2019 Jun; 138():6-13. PubMed ID: 31092386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary Acute Myeloid Leukemia: A Primary Challenge of Diagnosis and Treatment.
    Winer ES
    Hematol Oncol Clin North Am; 2020 Apr; 34(2):449-463. PubMed ID: 32089222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TP53 signal pathway confers potential therapy target in acute myeloid leukemia.
    Zhu G; Cai J; Zhong H
    Eur J Haematol; 2023 May; 110(5):480-489. PubMed ID: 36692074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of mutations in TP53 mutated AML.
    Welch JS
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and pathologic features of secondary acute promyelocytic leukemia.
    Duffield AS; Aoki J; Levis M; Cowan K; Gocke CD; Burns KH; Borowitz MJ; Vuica-Ross M
    Am J Clin Pathol; 2012 Mar; 137(3):395-402. PubMed ID: 22338051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetic findings in adult secondary acute myeloid leukemia (AML): frequency of favorable and adverse chromosomal aberrations do not differ from adult de novo AML.
    Preiss BS; Bergmann OJ; Friis LS; Sørensen AG; Frederiksen M; Gadeberg OV; Mourits-Andersen T; Oestergaard B; Kerndrup GB;
    Cancer Genet Cytogenet; 2010 Oct; 202(2):108-22. PubMed ID: 20875873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
    Takahashi K; Wang F; Kantarjian H; Doss D; Khanna K; Thompson E; Zhao L; Patel K; Neelapu S; Gumbs C; Bueso-Ramos C; DiNardo CD; Colla S; Ravandi F; Zhang J; Huang X; Wu X; Samaniego F; Garcia-Manero G; Futreal PA
    Lancet Oncol; 2017 Jan; 18(1):100-111. PubMed ID: 27923552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia.
    McGraw KL; Nguyen J; Komrokji RS; Sallman D; Al Ali NH; Padron E; Lancet JE; Moscinski LC; List AF; Zhang L
    Haematologica; 2016 Aug; 101(8):e320-3. PubMed ID: 27081179
    [No Abstract]   [Full Text] [Related]  

  • 14. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
    Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L
    Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of the p53-KLF4-CEBPA Axis in Acute Myeloid Leukemia.
    Seipel K; Marques MT; Bozzini MA; Meinken C; Mueller BU; Pabst T
    Clin Cancer Res; 2016 Feb; 22(3):746-56. PubMed ID: 26408402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Core-binding factor acute myeloid leukemia: Heterogeneity, monitoring, and therapy.
    Solh M; Yohe S; Weisdorf D; Ustun C
    Am J Hematol; 2014 Dec; 89(12):1121-31. PubMed ID: 25088818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Core binding factor acute myeloid leukemia.
    Paschka P
    Semin Oncol; 2008 Aug; 35(4):410-7. PubMed ID: 18692691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
    Zhang L; McGraw KL; Sallman DA; List AF
    Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and new treatment approaches in TP53 mutated AML.
    Hunter AM; Sallman DA
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):134-144. PubMed ID: 31203995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapy-related myeloid neoplasms: what's in a name?
    Klimek VM; Tray NJ
    Curr Opin Hematol; 2016 Mar; 23(2):161-6. PubMed ID: 26779614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.